ArticleFrontiers in cardiovascular medicine2025
Effects of anesthetic agents on the evaluation of systolic and diastolic function in mice.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to optimize non-invasive echocardiographic evaluation of myocardial function in a mouse model of diastolic heart failure, emphasizing the methodological challenges in assessing diastolic and left atrial (LA) function. Recognizing that clinical human studies frequently assess cardiac performance in non-sedated subjects, this investigation compared systolic and diastolic functional outcomes in mice subjected to heart failure with preserved ejection fraction (HFpEF) using two anesthetic agents: Avertin (mild sedation) and isoflurane (deep sedation). Additionally, we present a histological and echocardiographic correlation of the LA changes in established HFpEF mouse model. Results: Mice received angiotensin II and phenylephrine (AngII/PE) infusions for 28 days, followed by comprehensive echocardiographic and histologic analysis, including advanced diastology and LA assessment. AngII/PE treatment produced a reproducible HFpEF phenotype, with multiorgan involvement. Cardiac function measurements revealed significantly greater declines in both systolic and diastolic function in isoflurane-sedated mice, while mice sedated with Avertin primarily exhibited worsening diastolic metrics. LA histology corroborated imaging findings, showing profound wall thinning, reduced cellularity, and fibrotic conversion by day 28, changes tightly linked to deteriorating diastolic performance. Conclusion: The study highlights the limitations of deep sedation in accurately reflecting physiological cardiac function and underscores the importance of standardized mild-sedation protocols for translational murine heart failure research. Unlike the ventricular thickening and cardiomyocyte hypertrophy typically seen with diastolic dysfunction, LA remodeling was characterized by myocardial thinning and fibrosis, suggesting a distinct and opposite to LV pathogenic process. These findings support prioritizing minimally sedated echocardiographic assessment for better translational relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.